Antibody-drug conjugates poised to move lung cancer treatment earlier, boosting response rates and targeting brain metastases

Experts highlight that antibody‑drug conjugates are reshaping non‑small cell lung cancer therapy, moving beyond their traditional role in later‑line settings.

The new agents have demonstrated higher response rates, especially when patients are selected based on specific biomarkers that predict benefit.

In addition to systemic activity, several conjugates show penetration of the central nervous system, offering a potential option for brain metastases.

These advances suggest a shift toward using ADCs earlier in the treatment pathway, potentially improving outcomes for a broader patient population.